The aim of this study was to assess the efficacy of radioactive iodine-131 ( 131 I) therapy for lymph node metastasis of differentiated thyroid cancer (DTC) and to identify influential factors using univariate and multivariate analyses to determine if identified factors influence the efficacy of treatment.
Background
Differentiated thyroid cancer (DTC) includes papillary thyroid cancer and follicular thyroid cancer. DTC incidence tops the list of cancers of the human endocrine system and DTC rates are increasing every year [1, 2] . Studies have confirmed the efficacy of 131 I in ablation of thyroid remnants, treatment of metastasis after ablation operation, and as a prognostic indicator [3] [4] [5] . Three stages of treatment of DRC have been suggested as optimal treatment strategies: the total or subtotal ablation of thyroid tissues, the postoperative ablation of thyroid remnants with 131 I therapy, and the administration of thyroid hormone suppression treatment. Follow-up metrics for DTC patients include thyroglobulin (HTG) levels, single-photon emission computed tomography (SPECT)/CT, ultrasound, chest CT, and 131 I whole body scan. DTC generally has a good prognosis, but lymph node metastasis may occur at an early stage, which can have a negative impact on the prognosis of DTC. Many studies have shown that the metastasis rate of cervical lymph nodes ranges from 15% to 80% [7] [8] [9] . Nevertheless, 
Material and Methods

Clinical materials
We conducted a retrospective analysis of 218 patients with histologically proven DTC after thyroidectomy, of which 187 patients had papillary thyroid cancer and 31 patients had follicular thyroid cancer. Of the 218 patients, 64 were male and 154 were female; the average age ranged from 32 to 56 (43.73±12.12) years. Treatment for 94 patients was with total thyroidectomy or subtotal thyroidectomy, while the remaining 124 patients underwent a combination of total thyroidectomy and cervical lymph node dissection (of which 76 patients had unilateral lymph node dissection and 48 patients had bilateral lymph node dissection). After treatment with 131 I for ablation of thyroid remnants (with a dosage of 3.7 GBq), 406 lymph nodes of 218 patients were found to have metastases using ultrasound and therapeutic-dosage 131 I whole body scan. Three hundred and forty-seven lymph nodes were <2 cm and 59 lymph nodes were ³2 cm; the largest lymph node was 3.4×2.5×1.9 cm. I therapy to ensure thyroid-stimulating hormone (TSH) levels were >30 uIU/mL). All patients had routine blood tests (TSH, HTG, and HTGAb), and chest radiograph, cervical neck ultrasound, and 131 I whole body scan (185 MBq). After a week of 131 I therapy, the patients were given prednisone and vitamin C to mitigate local symptoms as well as to protect their salivary glands and parotid glands [12] . On the sixth day of 131 I therapy, the patients were given a therapeutic-dosage 131 I whole body scan, and if the patients showed no signs of getting better after the first course of treatment, the second therapeutic activity was administered under the same conditions only with 5.55 GBq 131 I. All patients had £2 treatments.
Treatment methods
Lymph node metastasis in DTC patients
Criteria of treatment efficacy
Methods to assess the efficacy of I whole body scan showed images of lesions that were faded; and the HTG level decreased, but was still ³2 μg/mL. (3) Non-effective Rate (NR). The lymph nodes did not shrink but tended to enlarge in size or increase in number; no obvious changes or no signs of densification were shown on 131 I whole body scan; and no changes were seen in HTG level. If a patient presented with several metastatic lymph nodes, the ineffectiveness of treatment was defined as either of the following: enlargement of any single lymph node, or increase in lymph node number.
Observation factors
The influences of nine factors on treatment efficacy were analyzed and included: age, gender, pathological type of cancer (papillary cancer or follicular cancer), operation methods, condition of distant metastasis, number of metastatic lymph nodes, number of lymph nodes, HTG level, and condition of thyroid remnant ablation. All tissue samples were provided and recorded by clinical doctors with over 10 years experience treating lymph node metastasis of DTC with 131 I therapy.
This study was approved by the Hebei Medical University Ethical Committee, Hebei, China. The nature, purpose, and potential risks of the study were explained to each participant prior to enrollment. Written informed consent was obtained from all enrolled patients.
Statistical analysis
All statistics were analyzed using the SPSS 17.0 statistical software package. The univariate analysis was conducted through chi-square test, and the multivariate analysis through logistic regression analysis.
Results
Treatment efficacy of 131 I to lymph node metastasis
The 218 patients with lymph node metastasis of DTC underwent 131 I therapy once or twice. Of these, 45 patients became free of disease with a cure rate of 20.64%; 147 patients had improved conditions, for an improvement rate of 67.43%; and 26 patients were treated non-effectively; thus, the total effective rate (cure plus improvement) for 131 I therapy was 88.07%, and the non-effective rate was 11.93%. Of the total 406 lymph nodes, 319 (78.57%) were treated effectively: 133 (32.75%) were totally removed after 131 I therapy, and 186 (45.82%) had shrunk. In addition, 87 (21.43%) of the 406 lymph nodes had no obvious changes, and none of lymph nodes were found to be in a continuously enlarged state.
Results of univariate analysis
The univariate analysis showed that age, condition of distant metastasis, size of lymph nodes, number of lymph nodes, HTG level, and condition of first-time thyroid remnant ablation had statistical significance, while gender, pathological type, and operation method had no statistical significance ( Table 1) .
Results of multivariate analysis
Factors from the univariate analysis that showed significant influence on treatment efficacy were then used in a logistic multivariate regression analysis model; the factors used were: age, condition of distant metastasis, size of lymph nodes, number of lymph nodes, HTG level, and condition of thyroid remnant ablation with 131 I. As a result, the condition of distant metastasis, size of lymph nodes, HTG level, and condition of thyroid remnant ablation with 131 I were defined as independent factors influencing the efficacy of treatment (p<0.05) ( 
